Source comparison
Tesamorelin vs CJC-1295
CJC-1295 is a modified GHRH analog that has never received FDA approval for any indication. It exists in two forms: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC (also called modified GRF 1-29 or MOD-GRF 1-29). The DAC version extends the
This comparison does not assign a generated winner or score.
- CJC-1295 is a modified GHRH analog that has never received FDA approval for any indication. It exists in two forms: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC (also called modified GRF 1-29 or MOD-GRF 1-29).
- The DAC version extends the half-life to 6 to 8 days, producing sustained GH elevation rather than pulsatile release. The FDA reviewed CJC-1295 with DAC for its Pharmacy Compounding Advisory Committee in 2024 and it was removed from the Category 2 compounding list, making it unavailable through standard compounding channels in the US.
- CJC-1295 has no Phase 3 trial data, no long-term human safety studies, and no FDA-verified manufacturing standards. The evidence for its efficacy comes from Phase 1/2 data and clinical observation.
- For detailed head-to-head analysis, see tesamorelin vs CJC-1295. To estimate dosing for CJC-1295 combinations, use the CJC-1295 + ipamorelin dosage calculator.